Gentherm acquires Innovative Medical Equipment to expand medical portfolio

0 min read Updated on 23 Jul 2026, 04:26 AM

Reviewed by

Suketu GScanX News Team

AI Summary

Gentherm acquired Innovative Medical Equipment, LLC (IME), adding the ThermaZone thermal therapy device to its portfolio. The acquisition strengthens Gentherm's Medical business, though financial terms were not disclosed.

*this image is generated using AI for illustrative purposes only.

Gentherm (NASDAQ: THRM) has acquired Innovative Medical Equipment, LLC (IME), a Cleveland-area provider of the ThermaZone thermal therapy device, to strengthen its Medical business. The acquisition supports Gentherm's strategy to expand its product portfolio through a strategic investment. Financial terms of the transaction were not disclosed.

Acquisition Details

The deal adds the ThermaZone thermal therapy device to Gentherm's existing portfolio. IME is based in the Cleveland area and specializes in thermal therapy solutions. This move aligns with Gentherm's goal to enhance its presence in the medical sector.

Strategic Impact

Gentherm stated that the acquisition is part of its broader strategy to grow its Medical business. By integrating IME's offerings, Gentherm aims to diversify its product range and leverage its expertise in thermal management technologies.

How will the acquisition of IME impact Gentherm's revenue growth in the medical sector over the next fiscal year?

What are the potential challenges Gentherm might face in integrating IME's ThermaZone device into its existing product lineup?

Could this acquisition signal further expansion into other medical device categories by Gentherm?

Read Next Article

Gentherm receives FDA clearance for ThermAffyx Patient Safety System

1 min read Updated on 21 Jul 2026, 02:34 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

AI Summary

Gentherm received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device combining active patient warming, securement, and pressure reduction for robotic-assisted surgeries. The system addresses safety gaps in over 3 million annual procedures, with trials starting in August and revenue expected in Q3 2026.

*this image is generated using AI for illustrative purposes only.

Gentherm has received FDA 510(k) clearance for its patented ThermAffyx Patient Safety System, a Class II medical device designed to enhance safety in robotic-assisted surgical procedures. The system integrates active patient warming, securement, and pressure reduction into a single platform, addressing a critical gap in the more than 3 million robotic-assisted surgeries performed annually worldwide. Revenue generation from the product is expected to commence in Q3 2026, following product trials at healthcare facilities scheduled to begin in August.

Addressing Surgical Safety Gaps

Historically, surgical teams have relied on separate solutions to manage patient warming and securement, a process that the ThermAffyx system aims to simplify. Traditional underbody securement pads prevent patient movement but lack active warming capabilities, a significant limitation during robotic procedures requiring the Trendelenburg position. Studies indicate that only 17% to 21% of a patient's body surface area is available for forced-air warming during these procedures, leading to hypothermia in more than one-quarter of robotic surgery patients despite warming interventions.

Technology and Portfolio Expansion

The ThermAffyx Patient Safety System integrates active underbody warming directly into an anti-slip securement pad, utilizing a radiolucent heating element powered by Gentherm's proprietary Carbotex carbon-fiber heating technology. This development represents a significant expansion of Gentherm's patient temperature management portfolio, following the company's 510(k) submission announced earlier this year.

Feature	Description
Device Class	Class II medical device
Key Functions	Active patient warming, securement, pressure reduction
Target Procedure	Robotic-assisted surgeries
Heating Technology	Proprietary Carbotex carbon-fiber heating technology
Trial Start Date	August
Expected Revenue Start	Q3 2026